Allergy Therapeutics Plc Ord 0.1P is listed on the London Stock Exchange trading with ticker code AGY.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £9,065m, with approximately 636m shares in issue.
Allergy Therapeutics Plc, officially known as Allergy Therapeutics Plc Ord 0.1P was formed in June of 2004, making the company fifteen years old. The company filed its latest accounts on 30th June 2014, showing a turnover of approximately 41.96 million GBX with gross profits of 30.00 million, or 0.0472 per issued share, and a pre-tax profit margin of 2.58%. Allergy Therapeutics Plc currently has 6 directors, and has had 8 previous directors over the last 15 years. In the last set of accounts produced by Grant Thornton Uk Llp, the company showed 18.44 million paid in salaries to the 347 staff (average wage of 53 thousand), with the directors receiving an average 141 thousand each. In the accounts filed in 2014, the company paid 0 in dividends. These accounts also showed Allergy Therapeutics Plc to have a net worth of 11.30 million, with 2.03 million held in cash.
Allergy Therapeutics Plc is in the Medicine and Biotech Research sector.
|Verona Pharma Plc Ord 0.1P (VRP.L)|
|Inland Homes Plc (INL.L)|
|Horizon Discovery Group Plc (HZD.L)|
|Interquest Group Plc (ITQ.L)|
|Somero Enterprise Inc. Com Stk Usd0.001 (Di) (SOM.L)|
|Shares in Issue||636m|
|52 Week High||0.00|
|52 Week Low||0.00|